Healthcare entity
Every one of those 1 sits in a single category, market-trends. RayzeBio is most often covered alongside Bristol Myers Squibb, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention RayzeBio, all published on July 8, 2026.
Last mentioned: Jul 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. RayzeBio is most often covered alongside Bristol Myers Squibb, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention RayzeBio, all published on July 8, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RayzeBio. Shared-story counts are live from our verified record — not editorial picks.
Pfizer and Bristol Myers Squibb combine high dividend yields with deep healthcare pipelines, offering a compelling income-entry into a sector facing patent cliffs but also rich in innovation. For healthcare investors, the stocks demand a long-term view on drug development amid evolving policy risks.
Source: The Motley Fool · fool.com
RayzeBio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
